A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies

Biotechnology and Bioengineering

Volumn 108, Issue 10, 2011, Pages 2434-2446

  Kim, Minsoo ^a,c   O'Callaghan, Peter M ^a   Droms, Kurt A ^b   James, David C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PFIZER INC   (United States)

^c Celltrion Inc   (South Korea)

Author keywords

Chinese hamster ovary cells; DNA methylation; Monoclonal antibody; Production instability

Indexed keywords

BIOPROCESSING; CELL LINES; CHINESE HAMSTER OVARY CELLS; CHO CELL; CMV PROMOTER; DNA METHYLATION; EXPRESSION SYSTEM; GENE SILENCING; GENE TRANSCRIPTIONS; GENETIC INSTABILITY; MAMMALIAN CELLS; MOLECULAR MECHANISM; PRIMARY MECHANISM; PRODUCTION CELLS; RECOMBINANT MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SPECIFIC PRODUCTIVITY; TRANSCRIPTIONAL SILENCING; UNDERLYING CAUSE;

ALKYLATION; ANIMAL CELL CULTURE; CELL PROLIFERATION; CELLS; GENES; GENETIC ENGINEERING; MAMMALS; METHYLATION; MONOCLONAL ANTIBODIES; PROTEINS; STABILITY; SURFACE PLASMON RESONANCE; TRANSCRIPTION; UNDERPINNINGS;

CYTOLOGY;

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G1 MONOCLONAL ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G2 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CELL CULTURE; CELL LINE; CELL POPULATION; CELL PROLIFERATION; CHO CELL; CYTOMEGALOVIRUS; DNA METHYLATION; EPIGENETICS; GENE DOSAGE; GENE EXPRESSION SYSTEM; GENE LOSS; GENE SILENCING; GENETIC RECOMBINATION; KINETICS; MOLECULAR MODEL; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PROMOTER REGION; RECOMBINANT GENE; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; HAMSTER; HUMAN;

CRICETULUS GRISEUS; MAMMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; CRICETULUS; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION; GENE SILENCING; HUMANS; IMMUNOGLOBULIN G; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC;

EID: 80051786735     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23189     Document Type: Article

References (60)

1. Barnes LM, Bentley CM, Dickson AJ. 2001. Characterization of the stability of recombinant protein production in the GS-NS0 expression system. Biotechnol Bioeng 73: 261-270.
2. Barnes LM, Bentley CM, Dickson AJ. 2004. Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnol Bioeng 85: 115-121.
3. Barnes LM, Moy N, Dickson AJ. 2006. Phenotypic variation during cloning procedures: analysis of the growth behavior of clonal cell lines. Biotechnol Bioeng 94: 530-537.
4. Barnes LM, Bentley CM, Moy N, Dickson AJ. 2007. Molecular analysis of successful cell line selection in transfected GS-NS0 myeloma cells. Biotechnol Bioeng 96: 337-348.
5. Bi JX, Shuttleworth J, Al-Rubeai M. 2004. Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1-arrested CHO cells. Biotechnol Bioeng 85: 741-749.
6. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103: 18238-18242.
7. Birch JR, Racher AJ. 2006. Antibody production. Adv Drug Deliv Rev 58: 671-685.
8. Campanero MR, Armstrong MI, Flemington EK. 2000. CpG methylation as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA 97: 6481-6486.
9. Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, Wong NS, Yap MG. 2009. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnol Bioeng 102: 1182-1196.
10. Clouaire T, Stancheva I. 2008. Methyl-CpG binding proteins: Specialized transcriptional repressors or structural components of chromatin? Cell Mol Life Sci 65: 1509-1522.
11. Derouazi M, Martinet D, Besuchet Schmutz N, Flaction R, Wicht M, Bertschinger M, Hacker DL, Beckmann JS, Wurm FM. 2006. Genetic characterization of CHO production host DG44 and derivative recombinant cell lines. Biochem Biophys Res Commun 340: 1069-1077.
12. Eckert KA, Hile SE. 2009. Every microsatellite is different: Intrinsic DNA features dictate mutagenesis of common microsatellites present in the human genome. Mol Carcinog 48: 379-388.
13. Eldar A, Elowitz MB. 2010. Functional roles for noise in genetic circuits. Nature 467: 167-173.
14. Fann CH, Guirgis F, Chen G, Lao MS, Piret JM. 2000. Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. Biotechnol Bioeng 69: 204-212.
15. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89: 1827-1831.
16. Garrick D, Fiering S, Martin DI, Whitelaw E. 1998. Repeat-induced gene silencing in mammals. Nat Genet 18: 56-59.
17. Gorman C, Arope S, Grandjean M, Girod PA, Mermod N. 2009. Use of MAR elements to increase the production of recombinant proteins. Cell Line Develop, Cell Eng 6: 1-32.
18. Greenwood SK, Hill RB, Sun JT, Armstrong MJ, Johnson TE, Gara JP, Galloway SM. 2004. Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. Environ Mol Mutagen 43: 36-44.
19. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. 2009. Mechanisms of change in gene copy number. Nat Rev Genet 10: 551-564.
20. Hayatsu H. 2008. The bisulfite genomic sequencing used in the analysis of epigenetic states, a technique in the emerging environmental genotoxicology research. Mutat Res 659: 77-82.
21. Heller-Harrison RA, Crowe K, Cooley C, Hone M, McCarthy K, Leonard M. 2009. Managing cell line instability and its impact during cell line development. BioPharm Int Suppl.
22. Illingworth RS, Bird AP. 2009. CpG islands-'a rough guide'. FEBS Lett 583: 1713-1720.
23. Imhof MO, Chatellard P, Kobr M, Pankiewicz R, Duverger V, Bagnound L, Sauvage C, Mossu C. 2009. Expression engineering-The IE2 promoter/enhancer from mouse CMV. Cell Line Develop, Cell Eng 6: 33-52.
24. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ. 2004. Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. Mol Biol Rep 31: 85-90.
25. Jun SC, Kim MS, Hong HJ, Lee GM. 2006. Limitations to the development of humanized antibody producing Chinese hamster ovary cells using glutamine synthetase-mediated gene amplification. Biotechnol Prog 22: 770-780.
26. Kalwy S, Rance J, Young R. 2006. Toward more efficient protein expression: Keep the message simple. Mol Biotechnol 34: 151-156.
27. Khoo SH, Al-Rubeai M. 2009. Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells. Biotechnol Bioeng 102: 188-199.
28. Kim SJ, Lee GM. 1999. Cytogenetic analysis of chimeric antibody-producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 64: 741-749.
29. Kim NS, Kim SJ, Lee GM. 1998a. Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: Stability in the absence of selective pressure. Biotechnol Bioeng 60: 679-688.
30. Kim SJ, Kim NS, Ryu CJ, Hong HJ, Lee GM. 1998b. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 58: 73-84.
31. Klose RJ, Bird AP. 2006. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31: 89-97.
32. Knust B, Brüggemann U, Doerfler W. 1989. Reactivation of a methylation-silenced gene in adenovirus-transformed cells by 5-azacytidine or by E1A trans activation. J Virol 63: 3519-3524.
33. Lang D, Fickenscher H, Stamminger T. 1992. Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Res 20: 3287-3295.
34. Lee GM, Varma A, Palsson BO. 1991. Application of population balance model to the loss of hybridoma antibody productivity. Biotechnol Prog 7: 72-75.
35. Loeb LA. 2001. A mutator phenotype in cancer. Cancer Res 61: 3230-3239.
36. McBurney MW, Mai T, Yang X, Jardine K. 2002. Evidence for repeat-induced gene silencing in cultured Mammalian cells: inactivation of tandem repeats of transfected genes. Exp Cell Res 274: 1-8.
37. Meilinger D, Fellinger K, Bultmann S, Rothbauer U, Bonapace IM, Klinkert WE, Spada F, Leonhardt H. 2009. Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells. EMBO Rep 10: 1259-1264.
38. Michel ML, Sobczak E, Malpiece Y, Tiollais P, Streeck RE. 1985. Expression of amplified hepatitis B virus surface antigen genes in Chinese hamster ovary cells. Biotechnology 3: 561-566.
39. Migliaccio AR, Bengra C, Ling J, Pi W, Li C, Zeng S, Keskintepe M, Whitney B, Sanchez M, Migliaccio G, Tuan D. 2000. Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562cells. Gene 256: 197-214.
40. Murphy JC, Fischle W, Verdin E, Sinclair JH. 2002. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J 21: 1112-1120.
41. O'Callaghan PM, James DC. 2008. Systems biotechnology of mammalian cell factories. Brief Funct Genomic Proteomic 7: 95-110.
42. O'Callaghan PM, McLeod J, Pybus LP, Lovelady CS, Wilkinson SJ, Racher AJ, Porter A, James DC. 2010. Cell line-specific control of recombinant monoclonal antibody production by CHO cells. Biotechnol Bioeng 106: 938-951.
43. Pallavicini MG, DeTeresa PS, Rosette C, Gray JW, Wurm FM. 1990. Effects of methotrexate on transfected DNA stability in mammalian cells. Mol Cell Biol 10: 401-404.
44. Pfaffl MW, Georgieva TM, Georgiev IP, Ontsouka E, Hageleit M, Blum JW. 2002. Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in the bovine species. Domest Anim Endocrinol 22: 91-102.
45. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ. 1999. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 27: 426-428.
46. Porter AJ, Racher AJ, Preziosi R, Dickson AJ. 2010. Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Improving the efficiency of cell line generation. Biotechnol Prog. 26: 1455-1464.
47. Rainaldi G, Meneveri R, Mariani L, Ginelli E, Moretti A, Vatteroni L. 1996. dCTP misincorporation in a Chinese hamster mutator phenotype: The role of GGA genetic context. Mutagenesis 11: 401-404.
48. Richards EJ, Elgin SC. 2002. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108: 489-500.
49. Rosser JM, An W. 2010. Repeat-induced gene silencing of L1 transgenes is correlated with differential promoter methylation. Gene 456: 15-23.
50. Rozenberg JM, Shlyakhtenko A, Glass K, Rishi V, Myakishev MV, FitzGerald PC, Vinson C. 2008. All and only CpG containing sequences are enriched in promoters abundantly bound by RNA polymerase II in multiple tissues. BMC Genomics 9: 67-80.
51. Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. 2005. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog 21: 122-133.
52. Siegfried Z, Simon I. 2010. DNA methylation and gene expression. Wiley Interdiscip Rev Syst Biol Med 2(3): 362-371.
53. Stinski MF, Isomura H. 2008. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med Microbiol Immunol 197: 223-231.
54. Strutzenberger K, Borth N, Kunert R, Steinfellner W, Katinger H. 1999. Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. J Biotechnol 69: 215-226.
55. Wade PA. 2001. Methyl CpG-binding proteins and transcriptional repression. Bioessays 23: 1131-1137.
56. Wright A, Semyonov A, Dawes G, Crameri A, Lyons R, Stemmer WP, Apt D, Punnonen J. 2005. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters. Hum Gene Ther 16: 881-892.
57. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22: 1393-1398.
58. Yang Y, Mariati, Chusainow J, Yap MG. 2010. DNA methylation contributes to loss in productivity of monoclonal antibody-producing CHO cell lines. J Biotechnol 147: 180-185.
59. Yoshikawa T, Nakanishi F, Itami S, Kameoka D, Omasa T, Katakura Y, Kishimoto M, Suga K. 2000a. Evaluation of stable and highly productive gene amplified CHO cell line based on the location of amplified genes. Cytotechnology 33: 37-46.
60. Yoshikawa T, Nakanishi F, Ogura Y, Oi D, Omasa T, Katakura Y, Kishimoto M, Suga K. 2000b. Amplified gene location in chromosomal DNA affected recombinant protein production and stability of amplified genes. Biotechnol Prog 16: 710-715.